ERBB2 and interstitial lung disease: While we accounted for duration of HER2-directed therapy in the metastatic setting by allowing it to determine length of follow-up in a subset of our time-to-event analyses, dosage during follow-up, duration of HER2-directed therapy in the neoadjuvant or adjuvant settings, dosing and duration of thoracic radiation, and dosing and duration of other ILD-inducing medication use were not evaluated in this analysis.